4-Acetoxy-N,N-dimethyltryptamine (also known as 4-AcO-DMT, 4-Acetoxy-DMT, O-Acetylpsilocin, and Psilacetin) is a novel psychedelic substance of the tryptamine class that produces an array of “classical psychedelic” effects when administered. Its effects are often compared to those produced by entheogenic tryptamines like psilocybin mushrooms and DMT. It is typically taken orally, less commonly via insufflation and rarely, via injection.
This compound has been proposed by psychedelics researcher David Nichols to be a potentially useful alternative to psilocybin for pharmacological research as they are both believed to act as prodrugs for psilocin (4-HO-DMT), the primary active component of psilocybin mushrooms. Its structural similarities to psilocin and psilocybin are thought to account for the near identical effects they produce and the three compounds are often considered to be interchangeable with each other.
Additionally, it is widely believed to have a similar if not near-identical toxicity profile as psilocybin itself, which makes it unusually physically benign and toxicologically predictable for a research chemical.
4-AcO-DMT and several other esters of psilocin were originally patented on January 16, 1963 by Sandoz Ltd. via Albert Hofmann & Franz Troxler. Despite this, 4-AcO-DMT has a limited history of use prior to its release as a grey area compound on the online research chemical market, where it has over time gained a sizable cult following due to its reputation for producing classical entheogenic effects despite being a purely synthetic substance in origin.
After being exclusively distributed on the online grey-market for many years, 4-AcO-DMT has recently been documented being sold as “shroom pills” on the street (either in the form of pressed tablets or gel capsules)